Patient reported outcome measures in a large cohort of patients with type 1 Gaucher disease.
Adult patients
Gaucher disease
Mobile survey
Patients reported outcome
Quality of life
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
13 10 2020
13 10 2020
Historique:
received:
27
07
2020
accepted:
14
09
2020
entrez:
14
10
2020
pubmed:
15
10
2020
medline:
22
6
2021
Statut:
epublish
Résumé
It is now acknowledged that the input of patients in health outcome assessment is vital to understanding the impact of diseases and interventions for those diseases. This study is the first report of patient-reported outcome measures (PROM) in a large cohort of patients with type 1 Gaucher disease (GD1) enabling us to study predictors of the reported outcomes. The PROM was sent via a mobile phone survey to 405 adult patients with GD1. Demographics, clinical data, and treatment status were extracted from clinic charts. Age, sex, severity score index (SSI) at presentation and treatment status were used as variables to assess outcomes. A total of 192 patients with GD1 (111 females) responded (47.4% response rate), of whom 124 (64.5%) had received GD1-specific therapy. Around 40% of patients reported that GD had restricted their education/job and fun activities and were concerned about being emotional and financial burdens on others. Concerns regarding the risk of bone disease and Parkinson disease were also high (60%). The severity of GD1 (reflected by the need for GD1-specific therapy and a high SSI) was associated with GD1-related restrictions and concerns, fatigue, physical weakness, bone pain, and worry regarding the future. The use of GD1 specific PROM highlights personal problems that are not captured by traditional outcome parameters and that need to be addressed to improve health-related quality of life. Validated PROM should be included among the outcome measures in clinical practice and future prospective studies for patients with chronic and rare diseases.
Sections du résumé
BACKGROUND
It is now acknowledged that the input of patients in health outcome assessment is vital to understanding the impact of diseases and interventions for those diseases. This study is the first report of patient-reported outcome measures (PROM) in a large cohort of patients with type 1 Gaucher disease (GD1) enabling us to study predictors of the reported outcomes.
METHOD
The PROM was sent via a mobile phone survey to 405 adult patients with GD1. Demographics, clinical data, and treatment status were extracted from clinic charts. Age, sex, severity score index (SSI) at presentation and treatment status were used as variables to assess outcomes.
RESULTS
A total of 192 patients with GD1 (111 females) responded (47.4% response rate), of whom 124 (64.5%) had received GD1-specific therapy. Around 40% of patients reported that GD had restricted their education/job and fun activities and were concerned about being emotional and financial burdens on others. Concerns regarding the risk of bone disease and Parkinson disease were also high (60%). The severity of GD1 (reflected by the need for GD1-specific therapy and a high SSI) was associated with GD1-related restrictions and concerns, fatigue, physical weakness, bone pain, and worry regarding the future.
CONCLUSIONS
The use of GD1 specific PROM highlights personal problems that are not captured by traditional outcome parameters and that need to be addressed to improve health-related quality of life. Validated PROM should be included among the outcome measures in clinical practice and future prospective studies for patients with chronic and rare diseases.
Identifiants
pubmed: 33050940
doi: 10.1186/s13023-020-01544-z
pii: 10.1186/s13023-020-01544-z
pmc: PMC7556970
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
284Références
Support Care Cancer. 2018 Nov;26(11):3721-3728
pubmed: 29732483
J Genet Couns. 2018 Feb;27(1):169-176
pubmed: 28803392
Blood Cells Mol Dis. 2013 Mar;50(3):218-21
pubmed: 23265741
Expert Rev Endocrinol Metab. 2018 Mar;13(2):107-118
pubmed: 30058864
BMJ. 2013 Jan 28;346:f167
pubmed: 23358487
Orphanet J Rare Dis. 2016 Apr 29;11(1):53
pubmed: 27129405
EBioMedicine. 2016 Sep;11:127-137
pubmed: 27515686
Blood. 2005 Jun 15;105(12):4569-72
pubmed: 15718419
JAMA Neurol. 2014 Jun;71(6):752-7
pubmed: 24756352
Mol Genet Metab. 2012 Jul;106(3):323-9
pubmed: 22592100
Neuron. 2017 Feb 22;93(4):737-746
pubmed: 28231462
Am J Med. 1994 Jul;97(1):1-2
pubmed: 8030649
Lancet. 1989 Aug 12;2(8659):349-52
pubmed: 2569551
Orphanet J Rare Dis. 2013 Sep 11;8:140
pubmed: 24020503
Orphanet J Rare Dis. 2018 Apr 23;13(1):61
pubmed: 29688860
Blood Cells Mol Dis. 2005 May-Jun;34(3):197-200
pubmed: 15885601
Blood Cells Mol Dis. 2018 Feb;68:203-208
pubmed: 28274788
Br J Haematol. 2018 Aug;182(4):467-480
pubmed: 29808905
Am J Hematol. 2018 Feb;93(2):205-212
pubmed: 29090476
Blood. 2018 May 31;131(22):2500-2501
pubmed: 29650800
Br J Haematol. 2013 Jun;161(6):832-42
pubmed: 23594419
J Inherit Metab Dis. 2018 Sep;41(5):819-827
pubmed: 29423829
Lancet. 2009 Aug 1;374(9687):369-70
pubmed: 19647598
Semin Immunol. 2018 Jun;37:30-42
pubmed: 29478824
J Health Commun. 2008 Jan-Feb;13(1):56-79
pubmed: 18307136
Am Soc Clin Oncol Educ Book. 2016;35:e89-96
pubmed: 27249775
Neurol Genet. 2016 Mar 04;2(2):e57
pubmed: 27123476
J Med Internet Res. 2015 May 07;17(5):e111
pubmed: 25953059
J Inherit Metab Dis. 2009 Dec;32 Suppl 1:S265-7
pubmed: 19562501
J Clin Med. 2019 Oct 11;8(10):
pubmed: 31614613
J Clin Epidemiol. 2016 Nov;79:10-21
pubmed: 27381737